As TIM-3 blockade attenuated galectin-9 induced apoptosis of tumor-infiltrating CD8+ T cells in vitro, we then tested whether this attenuation of apoptosis could be translated into improved tumor inhibition in vivo. The gene discussed is CD8A; the disease is neoplasm.